Use of Patient Preference Studies in HTA Decision Making: A NICE Perspective

Patient preference studies could provide valuable insights to a National Institute for Health and Care Excellence committee into the preferences patients have for different treatment options, especially if the study sample is representative of the broader patient population. We identify three main u...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:The patient : patient-centered outcomes research Ročník 13; číslo 2; s. 145 - 149
Hlavní autori: Bouvy, Jacoline C., Cowie, Luke, Lovett, Rosemary, Morrison, Deborah, Livingstone, Heidi, Crabb, Nick
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: Cham Springer International Publishing 01.04.2020
Springer Nature B.V
Predmet:
ISSN:1178-1653, 1178-1661, 1178-1661
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Abstract Patient preference studies could provide valuable insights to a National Institute for Health and Care Excellence committee into the preferences patients have for different treatment options, especially if the study sample is representative of the broader patient population. We identify three main uses of patient preference studies along a technology’s pathway from drug development to clinical use: in early clinical development to guide the selection of appropriate endpoints, to inform benefit-risk assessments carried out by regulators and to inform reimbursement decisions made by health technology assessment bodies. In the context of the National Institute for Health and Care Excellence’s methods and processes, we do not see a role for quantitative patient preference data to be directly incorporated into health economic modelling. Rather, we see a role for patient preference studies to be submitted alongside other types of evidence. Examples where patient preference studies might have added value in health technology assessments include cases where two distinctly different treatment options are being compared, when patients have to decide between multiple treatment options, when technologies have important non-health benefits or when a treatment is indicated for a heterogenous population.
AbstractList Patient preference studies could provide valuable insights to a National Institute for Health and Care Excellence committee into the preferences patients have for different treatment options, especially if the study sample is representative of the broader patient population. We identify three main uses of patient preference studies along a technology's pathway from drug development to clinical use: in early clinical development to guide the selection of appropriate endpoints, to inform benefit-risk assessments carried out by regulators and to inform reimbursement decisions made by health technology assessment bodies. In the context of the National Institute for Health and Care Excellence's methods and processes, we do not see a role for quantitative patient preference data to be directly incorporated into health economic modelling. Rather, we see a role for patient preference studies to be submitted alongside other types of evidence. Examples where patient preference studies might have added value in health technology assessments include cases where two distinctly different treatment options are being compared, when patients have to decide between multiple treatment options, when technologies have important non-health benefits or when a treatment is indicated for a heterogenous population.Patient preference studies could provide valuable insights to a National Institute for Health and Care Excellence committee into the preferences patients have for different treatment options, especially if the study sample is representative of the broader patient population. We identify three main uses of patient preference studies along a technology's pathway from drug development to clinical use: in early clinical development to guide the selection of appropriate endpoints, to inform benefit-risk assessments carried out by regulators and to inform reimbursement decisions made by health technology assessment bodies. In the context of the National Institute for Health and Care Excellence's methods and processes, we do not see a role for quantitative patient preference data to be directly incorporated into health economic modelling. Rather, we see a role for patient preference studies to be submitted alongside other types of evidence. Examples where patient preference studies might have added value in health technology assessments include cases where two distinctly different treatment options are being compared, when patients have to decide between multiple treatment options, when technologies have important non-health benefits or when a treatment is indicated for a heterogenous population.
Patient preference studies could provide valuable insights to a National Institute for Health and Care Excellence committee into the preferences patients have for different treatment options, especially if the study sample is representative of the broader patient population. We identify three main uses of patient preference studies along a technology's pathway from drug development to clinical use: in early clinical development to guide the selection of appropriate endpoints, to inform benefit-risk assessments carried out by regulators and to inform reimbursement decisions made by health technology assessment bodies. In the context of the National Institute for Health and Care Excellence's methods and processes, we do not see a role for quantitative patient preference data to be directly incorporated into health economic modelling. Rather, we see a role for patient preference studies to be submitted alongside other types of evidence. Examples where patient preference studies might have added value in health technology assessments include cases where two distinctly different treatment options are being compared, when patients have to decide between multiple treatment options, when technologies have important non-health benefits or when a treatment is indicated for a heterogenous population.
Patient preference studies could provide valuable insights to a National Institute for Health and Care Excellence committee into the preferences patients have for different treatment options, especially if the study sample is representative of the broader patient population. We identify three main uses of patient preference studies along a technology's pathway from drug development to clinical use: in early clinical development to guide the selection of appropriate endpoints, to inform benefitrisk assessments carried out by regulators and to inform reimbursement decisions made by health technology assessment bodies. In the context of the National Institute for Health and Care Excellence's methods and processes, we do not see a role for quantitative patient preference data to be directly incorporated into health economic modelling. Rather, we see a role for patient preference studies to be submitted alongside other types of evidence. Examples where patient preference studies might have added value in health technology assessments include cases where two distinctly different treatment options are being compared, when patients have to decide between multiple treatment options, when technologies have important nonhealth benefits or when a treatment is indicated for a heterogenous population.
Author Cowie, Luke
Crabb, Nick
Morrison, Deborah
Livingstone, Heidi
Lovett, Rosemary
Bouvy, Jacoline C.
Author_xml – sequence: 1
  givenname: Jacoline C.
  orcidid: 0000-0003-0093-5773
  surname: Bouvy
  fullname: Bouvy, Jacoline C.
  email: jacoline.bouvy@nice.org.uk
  organization: Science Policy and Research Programme, National Institute for Health and Care Excellence
– sequence: 2
  givenname: Luke
  surname: Cowie
  fullname: Cowie, Luke
  organization: Centre for Health Technology Evaluation, National Institute for Health and Care Excellence
– sequence: 3
  givenname: Rosemary
  surname: Lovett
  fullname: Lovett, Rosemary
  organization: Science Policy and Research Programme, National Institute for Health and Care Excellence
– sequence: 4
  givenname: Deborah
  surname: Morrison
  fullname: Morrison, Deborah
  organization: Scientific Advice, National Institute for Health and Care Excellence
– sequence: 5
  givenname: Heidi
  surname: Livingstone
  fullname: Livingstone, Heidi
  organization: Public Involvement Programme, National Institute for Health and Care Excellence
– sequence: 6
  givenname: Nick
  surname: Crabb
  fullname: Crabb, Nick
  organization: Science Policy and Research Programme, National Institute for Health and Care Excellence, Scientific Advice, National Institute for Health and Care Excellence
BackLink https://www.ncbi.nlm.nih.gov/pubmed/31942698$$D View this record in MEDLINE/PubMed
BookMark eNp9kUtPAyEYRYnR-P4DLgyJGzejMDA83DX11aRqE3VNBuarQVumwoyJ_160VRMXriDhHPi4dwethzYAQgeUnFBC5GnipJS0IFQXhHCiCr6GtimVqqBC0PWffcW20E5Kz4SIfCA20RajmpdCq200fkyA2yme1J2H0OFJhClECA7wfdc3HhL2AV8_DPA5OJ98G_BN_eLD0xke4NvR8AJPIKYFuM6_wR7amNazBPurdRc9Xl48DK-L8d3VaDgYF47JqiuctFVjpa2tbRpJpppWylIQ2ipBBIP8LVZVXNVKu1JxzjVrLKEAXKtKWM120fHy3kVsX3tInZn75GA2qwO0fTIlY1rqihGZ0aM_6HPbx5CnMyXXVFDJuMrU4Yrq7Rwas4h-Xsd3851TBsol4GKbUs7oB6HEfJZhlmWYXIb5KsPwLKk_kvNdzrkNXaz97H-VLdWU3wlPEH_H_sf6AIE1mgs
CitedBy_id crossref_primary_10_1183_23120541_00686_2021
crossref_primary_10_1080_17522439_2022_2095000
crossref_primary_10_1186_s12889_022_14244_z
crossref_primary_10_1007_s12325_022_02248_5
crossref_primary_10_2147_PPA_S442530
crossref_primary_10_1007_s40271_021_00521_3
crossref_primary_10_1136_rmdopen_2023_003031
crossref_primary_10_1007_s40271_024_00696_5
crossref_primary_10_1007_s40271_023_00650_x
crossref_primary_10_1177_0272989X231218265
crossref_primary_10_34067_KID_0000000000000377
crossref_primary_10_1371_journal_pone_0283926
crossref_primary_10_1080_14737167_2021_1880321
crossref_primary_10_3389_fpubh_2022_922708
crossref_primary_10_1007_s40271_020_00449_0
crossref_primary_10_1136_bmjopen_2025_101326
crossref_primary_10_1007_s40271_025_00760_8
crossref_primary_10_2217_fon_2021_0635
crossref_primary_10_3389_fpubh_2023_1176200
crossref_primary_10_1016_j_jclinepi_2023_07_003
crossref_primary_10_1007_s41669_025_00560_8
crossref_primary_10_1017_S0266462323000168
crossref_primary_10_1016_j_jval_2022_11_019
crossref_primary_10_1136_bmjonc_2025_000783
crossref_primary_10_1093_jphsr_rmab050
crossref_primary_10_1016_j_jclinepi_2024_111473
crossref_primary_10_1016_j_jval_2020_04_1831
crossref_primary_10_3389_fmed_2021_686165
crossref_primary_10_1007_s40271_023_00625_y
crossref_primary_10_1007_s10198_022_01482_6
crossref_primary_10_1017_S0266462324000242
crossref_primary_10_1080_03007995_2023_2291603
crossref_primary_10_1007_s40271_020_00433_8
crossref_primary_10_1007_s40271_020_00439_2
crossref_primary_10_1007_s40271_020_00450_7
crossref_primary_10_1017_S026646232400463X
crossref_primary_10_1007_s40273_022_01198_8
crossref_primary_10_1017_S0266462321000490
crossref_primary_10_1136_bmjopen_2021_058799
crossref_primary_10_3390_healthcare11030323
crossref_primary_10_3389_fpubh_2021_622154
crossref_primary_10_1007_s40271_021_00520_4
crossref_primary_10_2147_CEOR_S453171
crossref_primary_10_1007_s40271_024_00725_3
crossref_primary_10_1016_j_jval_2022_12_004
crossref_primary_10_1007_s12325_022_02367_z
crossref_primary_10_1007_s40271_022_00614_7
crossref_primary_10_1007_s40271_020_00446_3
crossref_primary_10_3389_fimmu_2022_883287
crossref_primary_10_1080_14737167_2023_2292838
crossref_primary_10_1016_j_sleepe_2025_100108
crossref_primary_10_1007_s43441_022_00432_x
crossref_primary_10_1007_s40271_022_00576_w
crossref_primary_10_1007_s40271_024_00676_9
crossref_primary_10_1002_cam4_6777
crossref_primary_10_1007_s43441_024_00725_3
crossref_primary_10_1007_s40271_023_00617_y
crossref_primary_10_1016_j_jval_2023_12_009
crossref_primary_10_2147_MDER_S368420
crossref_primary_10_1017_S0266462324000138
crossref_primary_10_1007_s11136_023_03416_y
crossref_primary_10_3389_fmed_2024_1408636
crossref_primary_10_1136_bmjopen_2023_076798
crossref_primary_10_1007_s41669_022_00376_w
crossref_primary_10_1007_s40271_021_00513_3
crossref_primary_10_1186_s12889_024_20951_6
crossref_primary_10_3389_fphar_2023_1192770
Cites_doi 10.1016/j.jval.2016.02.019
10.3389/fmed.2019.00082
10.1007/s40271-018-0305-9
10.1007/s00464-014-4044-2
10.1007/s40271-019-00367-w
10.1007/s40271-019-00396-5
10.1016/j.drudis.2017.09.016
10.1016/j.jval.2016.04.008
10.1002/cpt.332
ContentType Journal Article
Copyright Springer Nature Switzerland AG 2020
Copyright Springer Nature B.V. Apr 2020
Copyright_xml – notice: Springer Nature Switzerland AG 2020
– notice: Copyright Springer Nature B.V. Apr 2020
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
4T-
7RV
7X7
7XB
88E
8C1
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
FYUFA
GHDGH
K9-
K9.
KB0
M0R
M0S
M1P
NAPCQ
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
DOI 10.1007/s40271-019-00408-4
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Docstoc
ProQuest Nursing and Allied Health Journals - PSU access expires 11/30/25.
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Public Health Database
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central (subscription)
ProQuest One Community College
Health Research Premium Collection
Health Research Premium Collection (Alumni)
Consumer Health Database
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Database (Alumni Edition)
Consumer Health Database
ProQuest Health & Medical Collection
ProQuest Medical Database
Nursing & Allied Health Premium
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic (retired)
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Family Health (Alumni Edition)
ProQuest Central China
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Health & Medical Research Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Public Health
ProQuest Family Health
ProQuest One Academic Eastern Edition
ProQuest Nursing & Allied Health Source
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
Docstoc
ProQuest Nursing & Allied Health Source (Alumni)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE
ProQuest One Academic Middle East (New)

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7RV
  name: Nursing & allied health premium.
  url: https://search.proquest.com/nahs
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Public Health
EISSN 1178-1661
EndPage 149
ExternalDocumentID 31942698
10_1007_s40271_019_00408_4
Genre Journal Article
GeographicLocations United Kingdom
United States--US
GeographicLocations_xml – name: United Kingdom
– name: United States--US
GroupedDBID ---
-EM
04C
0R~
29O
3V.
4.4
406
53G
7RV
7X7
88E
8C1
8FI
8FJ
8R4
8R5
8UJ
95.
AACDK
AADNT
AAIKX
AAJKR
AAKAS
AASML
AATNV
ABAKF
ABDZT
ABFTV
ABIVO
ABJOX
ABKCH
ABKTR
ABLLE
ABPLI
ABTKH
ABTMW
ABUWG
ABXPI
ACAOD
ACCOQ
ACDTI
ACGFS
ACMLO
ACPIV
ACZOJ
ADBBV
ADFZG
ADURQ
ADZCM
ADZKW
AEFQL
AEJHL
AEJRE
AEMSY
AEOHA
AESKC
AFKRA
AFZKB
AGDGC
AGQEE
AGQMX
AHMBA
AHSBF
AIGIU
AILAN
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMXSW
ASPBG
AUKKA
AVWKF
AWSVR
AXYYD
AZQEC
BENPR
BGNMA
BKEYQ
BKNYI
BMSDO
BPHCQ
BVXVI
BYPQX
CAG
CCPQU
COF
DCUDU
DPUIP
EBS
EIHBH
EJD
EMOBN
EX3
F5P
FIGPU
FLLZZ
FNLPD
FSGXE
FYUFA
HMCUK
IAO
IEA
IHR
ITC
IWAJR
J-C
JZLTJ
K9-
LLZTM
M0R
M1P
M4Y
NAPCQ
NQJWS
NU0
O9-
OAC
OVD
PQQKQ
PROAC
PSQYO
Q2X
ROL
RSV
SISQX
SJYHP
SNPRN
SOHCF
SOJ
SPKJE
SRMVM
SSLCW
SV3
TEORI
TSG
U9L
UG4
UKHRP
UTJUX
VDBLX
VFIZW
W48
WOW
~JE
AAYXX
ABBRH
ABDBE
ABRTQ
AFDZB
AFFHD
ATHPR
AYFIA
CITATION
EBLON
PHGZM
PHGZT
PJZUB
PPXIY
CGR
CUY
CVF
ECM
EIF
NPM
4T-
7XB
8FK
K9.
PKEHL
PQEST
PQUKI
PRINS
7X8
PUEGO
ID FETCH-LOGICAL-c375t-c7b5db7babbdd70f9158b1e69b86063e40235548a89c2844493db01ee49856b93
IEDL.DBID RSV
ISICitedReferencesCount 72
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000507350700001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1178-1653
1178-1661
IngestDate Wed Oct 01 14:40:35 EDT 2025
Fri Nov 07 23:32:14 EST 2025
Thu Apr 03 07:10:00 EDT 2025
Sat Nov 29 02:34:21 EST 2025
Tue Nov 18 21:28:55 EST 2025
Fri Feb 21 02:30:23 EST 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed false
IsScholarly true
Issue 2
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c375t-c7b5db7babbdd70f9158b1e69b86063e40235548a89c2844493db01ee49856b93
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0003-0093-5773
PMID 31942698
PQID 2491617348
PQPubID 38894
PageCount 5
ParticipantIDs proquest_miscellaneous_2339795307
proquest_journals_2491617348
pubmed_primary_31942698
crossref_primary_10_1007_s40271_019_00408_4
crossref_citationtrail_10_1007_s40271_019_00408_4
springer_journals_10_1007_s40271_019_00408_4
PublicationCentury 2000
PublicationDate 20200400
2020-04-00
20200401
PublicationDateYYYYMMDD 2020-04-01
PublicationDate_xml – month: 4
  year: 2020
  text: 20200400
PublicationDecade 2020
PublicationPlace Cham
PublicationPlace_xml – name: Cham
– name: New Zealand
– name: Auckland
PublicationSubtitle An Official Journal of the International Academy of Health Preference Research
PublicationTitle The patient : patient-centered outcomes research
PublicationTitleAbbrev Patient
PublicationTitleAlternate Patient
PublicationYear 2020
Publisher Springer International Publishing
Springer Nature B.V
Publisher_xml – name: Springer International Publishing
– name: Springer Nature B.V
References National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013. Available from: https://www.nice.org.uk/process/pmg9/chapter/foreword. Accessed 30 Oct 2019.
National Institute for Health and Care Excellence. NICE provides first scientific advice on patient preference study design. 2019. Available from: https://www.nice.org.uk/news/article/nice-provides-first-scientific-advice-on-patient-preference-study-design. Accessed 30 Oct 2019.
HoMPGonzalezJMLernerHPNeulandCYWhangJMMcMurry-HeathMIncorporating patient-preference evidence into regulatory decision makingSurg Endosc.201529102984299310.1007/s00464-014-4044-2
JanssensRRussoSvan OverbeekeEPatient preferences in the medical product life cycle: what do stakeholders think? Semi-structured qualitative interviews in Europe and the USAPatient.20191251352610.1007/s40271-019-00367-w
PostmusDMavrisMHillegeHLSalmonsonTRyllBPlateAIncorporating patient preferences into drug development and regulatory decision making: results from a quantitative pilot study with cancer patients, carers, and regulatorsClin Pharmacol Ther.20169955485541:STN:280:DC%2BC28rlslKjsw%3D%3D10.1002/cpt.332
National Institute for Health and Care Excellence. Our research work. 2019. Available from: www.nice.org.uk/research. Accessed 30 Nov 2019.
Reed JohnsonFZhouMPatient preferences in regulatory benefit-risk assessments: a US perspectiveValue Health.201619674174510.1016/j.jval.2016.04.008
Institute for Quality and Efficiency in Health Care. Choice-based conjoint analysis: pilot project to identify, weight, and prioritize multiple attributes in the indication “hepatitis C”. Working paper (English summary). 2014. Available from: https://www.iqwig.de/en/projects-results/projects/health-economic/ga10-03-pilot-study-conjoint-analysis-in-the-indication-hepatitis-c.1411.html. Accessed 13 Sept 2019.
IMI PREFER. About PREFER. 2019. Available from: https://www.imi-prefer.eu/about/. Accessed 30 Oct 2019.
Cowie L, Bouvy J. Measuring patient preferences: an exploratory study to determine how patient preferences data could be used in health technology assessment (HTA). Myeloma UK, 2019. Available from: https://www.myeloma.org.uk/wp-content/uploads/2019/07/NICE-Patient-Preferences-Report.pdf. Accessed 30 Oct 2019.
MottDMIncorporating quantitative patient preference data into healthcare decision making processes: is HTA falling behind?Patient.20181124925210.1007/s40271-018-0305-9
CookNSCaveJHoltorfA-PPatient preference studies during early drug development: aligning stakeholders to ensure development plans meet patient needsFront Med (Lausanne).201968210.3389/fmed.2019.00082310692276491461
HoMSahaAMcClearyKKLevitanBChristopherSZandloKA framework for incorporating patient preferences regarding benefits and risks into regulatory assessment of medical technologiesValue Health.201619674675010.1016/j.jval.2016.02.019
BenzHLLeeTHJHua TsaiJAdvancing the use of patient preference information as scientific evidence in medical product evaluation: a summary report of the patient preference workshopPatient.20191255355710.1007/s40271-019-00396-5
ChaudhuriSEHoMPIronyTSheldonMLoAWPatient-centered clinical trialsDrug Discov Today.201823239540110.1016/j.drudis.2017.09.016
408_CR12
NS Cook (408_CR3) 2019; 6
408_CR15
408_CR13
408_CR14
M Ho (408_CR10) 2016; 19
D Postmus (408_CR11) 2016; 99
SE Chaudhuri (408_CR4) 2018; 23
408_CR2
HL Benz (408_CR8) 2019; 12
408_CR1
R Janssens (408_CR6) 2019; 12
DM Mott (408_CR7) 2018; 11
MP Ho (408_CR5) 2015; 29
F Reed Johnson (408_CR9) 2016; 19
References_xml – reference: National Institute for Health and Care Excellence. Our research work. 2019. Available from: www.nice.org.uk/research. Accessed 30 Nov 2019.
– reference: National Institute for Health and Care Excellence. NICE provides first scientific advice on patient preference study design. 2019. Available from: https://www.nice.org.uk/news/article/nice-provides-first-scientific-advice-on-patient-preference-study-design. Accessed 30 Oct 2019.
– reference: BenzHLLeeTHJHua TsaiJAdvancing the use of patient preference information as scientific evidence in medical product evaluation: a summary report of the patient preference workshopPatient.20191255355710.1007/s40271-019-00396-5
– reference: HoMPGonzalezJMLernerHPNeulandCYWhangJMMcMurry-HeathMIncorporating patient-preference evidence into regulatory decision makingSurg Endosc.201529102984299310.1007/s00464-014-4044-2
– reference: IMI PREFER. About PREFER. 2019. Available from: https://www.imi-prefer.eu/about/. Accessed 30 Oct 2019.
– reference: National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013. Available from: https://www.nice.org.uk/process/pmg9/chapter/foreword. Accessed 30 Oct 2019.
– reference: ChaudhuriSEHoMPIronyTSheldonMLoAWPatient-centered clinical trialsDrug Discov Today.201823239540110.1016/j.drudis.2017.09.016
– reference: CookNSCaveJHoltorfA-PPatient preference studies during early drug development: aligning stakeholders to ensure development plans meet patient needsFront Med (Lausanne).201968210.3389/fmed.2019.00082310692276491461
– reference: Cowie L, Bouvy J. Measuring patient preferences: an exploratory study to determine how patient preferences data could be used in health technology assessment (HTA). Myeloma UK, 2019. Available from: https://www.myeloma.org.uk/wp-content/uploads/2019/07/NICE-Patient-Preferences-Report.pdf. Accessed 30 Oct 2019.
– reference: JanssensRRussoSvan OverbeekeEPatient preferences in the medical product life cycle: what do stakeholders think? Semi-structured qualitative interviews in Europe and the USAPatient.20191251352610.1007/s40271-019-00367-w
– reference: MottDMIncorporating quantitative patient preference data into healthcare decision making processes: is HTA falling behind?Patient.20181124925210.1007/s40271-018-0305-9
– reference: PostmusDMavrisMHillegeHLSalmonsonTRyllBPlateAIncorporating patient preferences into drug development and regulatory decision making: results from a quantitative pilot study with cancer patients, carers, and regulatorsClin Pharmacol Ther.20169955485541:STN:280:DC%2BC28rlslKjsw%3D%3D10.1002/cpt.332
– reference: Reed JohnsonFZhouMPatient preferences in regulatory benefit-risk assessments: a US perspectiveValue Health.201619674174510.1016/j.jval.2016.04.008
– reference: HoMSahaAMcClearyKKLevitanBChristopherSZandloKA framework for incorporating patient preferences regarding benefits and risks into regulatory assessment of medical technologiesValue Health.201619674675010.1016/j.jval.2016.02.019
– reference: Institute for Quality and Efficiency in Health Care. Choice-based conjoint analysis: pilot project to identify, weight, and prioritize multiple attributes in the indication “hepatitis C”. Working paper (English summary). 2014. Available from: https://www.iqwig.de/en/projects-results/projects/health-economic/ga10-03-pilot-study-conjoint-analysis-in-the-indication-hepatitis-c.1411.html. Accessed 13 Sept 2019.
– volume: 19
  start-page: 746
  issue: 6
  year: 2016
  ident: 408_CR10
  publication-title: Value Health.
  doi: 10.1016/j.jval.2016.02.019
– volume: 6
  start-page: 82
  year: 2019
  ident: 408_CR3
  publication-title: Front Med (Lausanne).
  doi: 10.3389/fmed.2019.00082
– volume: 11
  start-page: 249
  year: 2018
  ident: 408_CR7
  publication-title: Patient.
  doi: 10.1007/s40271-018-0305-9
– volume: 29
  start-page: 2984
  issue: 10
  year: 2015
  ident: 408_CR5
  publication-title: Surg Endosc.
  doi: 10.1007/s00464-014-4044-2
– volume: 12
  start-page: 513
  year: 2019
  ident: 408_CR6
  publication-title: Patient.
  doi: 10.1007/s40271-019-00367-w
– volume: 12
  start-page: 553
  year: 2019
  ident: 408_CR8
  publication-title: Patient.
  doi: 10.1007/s40271-019-00396-5
– ident: 408_CR1
– ident: 408_CR15
– ident: 408_CR2
– volume: 23
  start-page: 395
  issue: 2
  year: 2018
  ident: 408_CR4
  publication-title: Drug Discov Today.
  doi: 10.1016/j.drudis.2017.09.016
– volume: 19
  start-page: 741
  issue: 6
  year: 2016
  ident: 408_CR9
  publication-title: Value Health.
  doi: 10.1016/j.jval.2016.04.008
– volume: 99
  start-page: 548
  issue: 5
  year: 2016
  ident: 408_CR11
  publication-title: Clin Pharmacol Ther.
  doi: 10.1002/cpt.332
– ident: 408_CR13
– ident: 408_CR14
– ident: 408_CR12
SSID ssj0061666
Score 2.4374592
Snippet Patient preference studies could provide valuable insights to a National Institute for Health and Care Excellence committee into the preferences patients have...
SourceID proquest
pubmed
crossref
springer
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 145
SubjectTerms Clinical decision making
Committees
Cost-Benefit Analysis
Current Opinion
Decision making
Drug Development
Experiments
Health Administration
Health Economics
Health services
Humans
Insurance, Health, Reimbursement
Medicine
Medicine & Public Health
Patient Preference
Patients
Pharmacoeconomics and Health Outcomes
Preferences
Public Health
Quality of Life Research
Regulatory agencies
Regulatory approval
Reimbursement
Risk Assessment
State Medicine - organization & administration
Technology Assessment, Biomedical - organization & administration
Testimony
United Kingdom
SummonAdditionalLinks – databaseName: ProQuest Central (subscription)
  dbid: BENPR
  link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3dS8MwED90E_HF74_5RQTfNLguaZr4InNuTJijyATfSpOmMJBO3ebfb9KmHSLuxefmi97lcpfL_X4Al0ZnGZGkiQVPCaaylWDBKMOaq1bsN5ngKseZHQTDIX99FaG7cJu6Z5WlTcwNdTJR9o78xoQJ1hUnlN-9f2DLGmWzq45CYxXqFqmM1qB-3x2Gz6UtZjYpVtCrmFiJ-cSVzeTFcyZyCmwoLbDVZI7pz6Ppl7_5K1eaH0G9rf8ufhs2nfOJ2oW27MCKznZh_cml1_dg8DLVaJKisABbRWFFQoLce0M0zlB_1EYPjpoHPeVsVreojYaPnS4KF7Wb-_DS6446fezoFrAigT_DKpB-IgMZS5kkQTMVns-lp5mQ3EQ5RFMLjWMCnJgLZQ41SgVJZNPTmgruMynIAdSySaaPAKXSt0D5MTPj0CQxXqTyYiKMbyh1GnDRAK_805FyWOSWEuMtqlCUc-lERjpRLp2INuCq6vNeIHEsbX1aSiJyu3IaLcTQgIvqs9lPNkkSZ3oyN22IzXT6xvQ14LAQfDWdMVe28tf0vi41YTH432s5Xr6WE9ho2SA-fw50CrXZ51yfwZr6mo2nn-dOo78B2ij2Ow
  priority: 102
  providerName: ProQuest
Title Use of Patient Preference Studies in HTA Decision Making: A NICE Perspective
URI https://link.springer.com/article/10.1007/s40271-019-00408-4
https://www.ncbi.nlm.nih.gov/pubmed/31942698
https://www.proquest.com/docview/2491617348
https://www.proquest.com/docview/2339795307
Volume 13
WOSCitedRecordID wos000507350700001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVPQU
  databaseName: Consumer Health Database
  customDbUrl:
  eissn: 1178-1661
  dateEnd: 20241207
  omitProxy: false
  ssIdentifier: ssj0061666
  issn: 1178-1653
  databaseCode: M0R
  dateStart: 20080101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/familyhealth
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Health & Medical Collection
  customDbUrl:
  eissn: 1178-1661
  dateEnd: 20241207
  omitProxy: false
  ssIdentifier: ssj0061666
  issn: 1178-1653
  databaseCode: 7X7
  dateStart: 20080101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Nursing & allied health premium.
  customDbUrl:
  eissn: 1178-1661
  dateEnd: 20241207
  omitProxy: false
  ssIdentifier: ssj0061666
  issn: 1178-1653
  databaseCode: 7RV
  dateStart: 20080101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/nahs
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl:
  eissn: 1178-1661
  dateEnd: 20241207
  omitProxy: false
  ssIdentifier: ssj0061666
  issn: 1178-1653
  databaseCode: BENPR
  dateStart: 20080101
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Proquest Public Health Database
  customDbUrl:
  eissn: 1178-1661
  dateEnd: 20241207
  omitProxy: false
  ssIdentifier: ssj0061666
  issn: 1178-1653
  databaseCode: 8C1
  dateStart: 20080101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/publichealth
  providerName: ProQuest
– providerCode: PRVAVX
  databaseName: SpringerLINK Contemporary Collection
  customDbUrl:
  eissn: 1178-1661
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0061666
  issn: 1178-1653
  databaseCode: RSV
  dateStart: 20080101
  isFulltext: true
  titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22
  providerName: Springer Nature
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3rS-QwEB98IQfi-3Q9lQh-uwu0mzSP-7a3rii4S1kf7LfStCkI0hV39e930qaVQz04vwRKkzRMMo9fJzMDcIpnVjDDAqpVwSg33ZxqwQW1KuumUSC0yqo8s1dyNFKTiY59UNisue3euCQrSd0GuyHSkQ76aupOnqJ8EZZR3SnHjuPru0b-CucIq0uqID4SEfOhMh_P8bc6emdjvvOPVmrnfONrC96EdW9mkl59LrZgwZbbsDr0jvRtWKt_15E6CmkHrm5nlkwLEtdpVknclh8h_qYhuS_JxU2PnPmiPGRY1bH6TXpkdNkfkPgtanMXbs8HN_0L6gst0IzJaE4zaaLcSJMak-cyKHQYKRNaoY1CfMMsd0lxENqkSmeozjjXLDdBaC3XKhJGs--wVE5Luw-kMJFLkZ8KnIfnOdqPWZgyjVahsYVUugNhQ-8k81nIXTGMh6TNn1yRLUGyJRXZEt6Bn-2YxzoHxz97HzbbmHh-nCUIMh2QY1x14KR9jZzk3CNpaafP2Ic5H2eEQq8De_X2t59DQeVifnH0r2av3yb_fC0H_9f9B3zrOjhfXQw6hKX507M9gpXsZX4_ezqGRTm-c-1EVq3CVvXDY1j-MxjFY3waBq5FXngFM0H17Q
linkProvider Springer Nature
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFD6aBgJeuG8UBhgJnsCiiR3HRkKo2kWt1lYV6tDeQuw40iSUjrUD8af2G3eOc6nQxN72wHNsx8k5_nzsc_kA3qLOKmFFnxtdCi5tXHCjpOJeuzhP-spoF-rMjtPpVB8fm9kGXLS5MBRW2WJiAOpi4eiO_CMeE8gUF1J_Of3JiTWKvKsthUatFof-z288si0_j_ZQvu_i-GB_vjvkDasAdyJNVtylNilsanNriyLtlyZKtI28MlajMS-8pAowaMfn2jjEbimNKGw_8l4anShLxZcQ8m8hjkcUQpZ-_dYivyIXXE3mgiczlYgmSSek6uGwKR3cDad1o7n8eyO8Yt1e8cyGDe_gwf_2qx7C_ca0ZoN6LTyCDV89hjuTJnjgCYyPlp4tSjarS8myWUexwppoSnZSseF8wPYa4iE2CVxdn9iATUe7-2y2zkx9Ckc38i1bsFktKv8MWGkTogHIFY4jiwJtZBflwqDla32ZatODqJVs5ppK60T48SPrakQHbchQG7KgDZnswfuuz2ldZ-Ta1jut5LMGc5bZWuw9eNM9RrQgF1Be-cU5thHkx00Q2HuwXSta9zoEY8prxt4fWs1bD_7vuTy_fi6v4e5wPhln49H08AXci-m6IgQ-7cDm6uzcv4Tb7tfqZHn2KqwlBt9vWiMvAdZ-UNg
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3NT9swFH9CDKFdtrEP1o0xT9pOm0UTO449aZqqloqKUuUAErcsdhwJaUoZLZv2r_HX8ew4qRCCGwfOsR0n_vn5Pb-PH8BnxKxgmvWpkhWjXMclVYILaqWJi6QvlDS-zuw0nc3k6anK1uCqzYVxYZWtTPSCupwbd0e-h2aCU8UZl3tVCIvIRuOf53-oY5ByntaWTqOByKH9_w_Nt8WPyQjX-kscj_ePhwc0MAxQw9JkSU2qk1KnutC6LNN-paJE6sgKpSUq9sxyVw0GdfpCKoNynHPFSt2PrOVKJkK7Qkwo_p-kDFHsstSHXXiJcO64htgFrTSRsJCw49P2cNjUGfGKuj0kKb95KN7SdG95af3hN37-mH_bC3gWVG4yaPbIFqzZ-iVsHoWgglcwPVlYMq9I1pSYJVlHvUJClCU5q8nB8YCMAiEROfIcXt_JgMwmw32SrTJWX8PJg3zLG1iv57V9C6TSiaMHKASOw8sSdWcTFUyhRqxtlUrVg6hd5dyECuyOCOR33tWO9sjIERm5R0bOe_C163Pe1B-5t_VOi4I8yKJFvoJADz51j1GKONdQUdv5JbZhzr-boMDvwXYDuu51KKRdvjP2_taicDX43XN5d_9cPsImAjGfTmaH7-Fp7G4xfDzUDqwvLy7tB9gwf5dni4tdv60I_HpoQF4DzKZZMw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Use+of+Patient+Preference+Studies+in+HTA+Decision+Making%3A+A+NICE+Perspective&rft.jtitle=The+patient+%3A+patient-centered+outcomes+research&rft.au=Bouvy%2C+Jacoline+C&rft.au=Cowie%2C+Luke&rft.au=Lovett%2C+Rosemary&rft.au=Morrison%2C+Deborah&rft.date=2020-04-01&rft.issn=1178-1661&rft.eissn=1178-1661&rft.volume=13&rft.issue=2&rft.spage=145&rft_id=info:doi/10.1007%2Fs40271-019-00408-4&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1178-1653&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1178-1653&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1178-1653&client=summon